» Articles » PMID: 34674650

Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease with or Without Cirrhosis: a Population-based Study

Overview
Publisher Biomed Central
Specialty Gastroenterology
Date 2021 Oct 22
PMID 34674650
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There are limited data regarding the factors associated with hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. We sought to determine the prevalence and factors associated with HCC in NAFLD patients with or without cirrhosis.

Methods: Adults with NAFLD (June 2015 to May 2020) were identified using the electronic health record database (Explorys Inc, Cleveland, OH) from 26 major integrated US healthcare systems. The prevalence of HCC was calculated. Multivariable analyses adjusting for covariates were performed to evaluate the associated risk factors and the presence of HCC.

Results: A total of 392,800 NAFLD patients were identified. Among 1110 patients with HCC, 170 (15.3%) had no cirrhosis. The prevalence of HCC in non-cirrhotic and cirrhotic NAFLD patients was 4.6/10,000 persons (95% CI 3.9-5.3), and 374.4/10,000 persons (95% CI 350.9-398.8), respectively. Age > 65 years (adjusted OR; 3.37, 95% CI 2.47-4.59), ever had elevated alanine aminotransferase (2.69; 2.14-3.37), male gender (2.57; 1.88-3.49), smoker (1.75; 1.23-2.49), and diabetes (1.56; 1.15-2.11) were associated with HCC in non-cirrhotic NAFLD (all P < 0.05). The prevalence of HCC in the non-cirrhotic with all five risk factors was 45.5/10,000 persons (95% CI 17.4-73.6). The factors associated with HCC in cirrhotic NAFLD included clinical decompensation, age > 65 years, male gender, Hispanic race, elevated alanine aminotransferase, diabetes and smoker (all P < 0.05).

Conclusions: These data identified the major risk factors for the development of HCC in NAFLD patients. In the non-cirrhotics, older male patients with smoking history, diabetes and an elevated alanine aminotransferase had highest risk and may need increased judicious monitoring.

Citing Articles

Risk-stratified hepatocellular carcinoma surveillance in non-cirrhotic patients with MASLD.

Mi K, Ye T, Zhu L, Pan C Gastroenterol Rep (Oxf). 2025; 13:goaf018.

PMID: 39980834 PMC: 11842057. DOI: 10.1093/gastro/goaf018.


Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study.

Kowada A BMJ Open. 2024; 14(11):e080549.

PMID: 39500609 PMC: 11552604. DOI: 10.1136/bmjopen-2023-080549.


Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022.

Park J, Yoo J, Lee D, Chang Y, Jo H, Cho Y Korean J Intern Med. 2024; 39(6):931-944.

PMID: 39444335 PMC: 11569921. DOI: 10.3904/kjim.2024.164.


Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma.

Liu Y, Peng F, Wang S, Jiao H, Zhou K, Guo W Clin Mol Hepatol. 2024; 31(1):196-212.

PMID: 39406379 PMC: 11791606. DOI: 10.3350/cmh.2024.0527.


Air pollutants and primary liver cancer mortality: a cohort study in crop-burning activities and forest fires area.

Thongsak N, Chitapanarux T, Chotirosniramit A, Chakrabandhu S, Traisathit P, Nakharutai N Front Public Health. 2024; 12:1389760.

PMID: 39381772 PMC: 11459313. DOI: 10.3389/fpubh.2024.1389760.


References
1.
Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R . Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int. 2015; 10(4):632-9. DOI: 10.1007/s12072-015-9679-0. View

2.
Lee T, Wu J, Yu S, Lin J, Wu M, Wu C . The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer. 2017; 141(7):1307-1314. DOI: 10.1002/ijc.30784. View

3.
Ertle J, Dechene A, Sowa J, Penndorf V, Herzer K, Kaiser G . Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2010; 128(10):2436-43. DOI: 10.1002/ijc.25797. View

4.
Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y . Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2011; 130(7):1639-48. DOI: 10.1002/ijc.26165. View

5.
Allen A, Therneau T, Larson J, Coward A, Somers V, Kamath P . Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2017; 67(5):1726-1736. PMC: 5866219. DOI: 10.1002/hep.29546. View